Benefits to Attending Hear from and meet with the people shaping the pharmaceutical landscape. 2017 attendees include: VPs of Discovery, Alkermes, Astra Zeneca, LEO, Lundbeck, MSD UCB; Senior Directors from Novartis, AbbVie, J&J, Gruenthal, Pfizer, Immunocore, Novimmune, Biogen Idec Discover collaborative solutions to small molecule and large molecule drug discovery challenges. This summit brings together experts on the best discovery techniques and technology, validating novel drug targets, improving lead optimisation in different therapeutic areas including Immuno- Therapy, Autoimmune, Oncology, Inflammatory, cardiovascular and metabolic diseases Explore innovative Phenotypic screening, target based as well as RNAi screening methods Gain from two discovery and computational chemistry streams to provide insights into modern medicinal chemistry strategies, computational chemistry, FEP in structured based design, DNA coded libraries, automation, and novel approaches to drug design A stratified program ensuring tailored content – Benefit from attending pre-event webinars, panel discussions and roundtable discussions on Novel Discovery Tools, Open Innovation, Artificial Intelligence, Phenotypic vs. target-based drug discovery, ADMET, Gene Editing and PROTAC Unparalleled networking opportunities. The two-day congress format combines dedicated networking breaks, pre-organised 1-2-1 meetings and our popular drinks reception. The exhibition hall and poster presentation spaces offer a relaxed and professional environment for discussion Co-located with the Microbiome Discovery & Development Congress Klaus Bæk Simonsen, Vice President, Lundbeck Markus Haeberlein, Vice President, Discovery, Alkermes, Nick Terrett ,Scientific Associate Vice Preside MSD Constance Höfer, Chief Operating Officer, Priaxon Peter Juhasz, Director, Mechanisms and Pathways, Biogen Guido Hanauer, Scient Director Translational Medicine, Takeda For booking details & registration fees please refer to the last page or visit: http://www.drugdiscovery-summit1.com/marketing Day 1 Stream 1: Drug Discovery Innovation and Strategies, Enabling Technologies Innovative Target Discovery and Discovery Models in: Metabolic and Cardiovascular Therapeutics, Cardiometabolic Drug Targets, Cancer Immunotherapy, Oncology and Neurological Diseases Strategies in Target Validation and Lead Optimization Managing Translational Informatics Data Management in Discovery Novel Drug Targets and Screening Tools Managing Complex Discovery Portfolios ADMET Drug Discovery Day 2 Stream 1: Novel Drug Target Discovery for Immuno-Therapy, Autoimmune Diseases and Oncology Discovery of T-Cell Cancer Immuno-Therapy Novel Therapies for Cancer and Emerging Targets Kinase Inhibitors: Cancer Immunotherapy Discovery, Autoimmune and Inflammatory Diseases, CNS and Neurodegenerative Disorders Cancer metabolism /cancer metabolism targets - including anti-cachexic strategies Day 1 Stream 2: Successful Phenotypic Drug Discovery: High Content Screening Techniques and Tools in High Content Technologies Phenotypic Screening Applications 3D Cell Based Screening Methods Using Model Organisms for Screening Methods Novel Approaches for Phenotypic Screening Using Patient-Derived Tumour Models for Screening Screening in Oncology and CNS Therapeutic Areas High Content Screening & Data Management Day 2 Stream 2: PART I - Open Innovation and Drug Discovery PART 2- RNAi Screening, Genomics Discovery and Gene Editing for Drug Discovery Applications for Invivo RNAi Screening Novel Applications in RNAi Screening High-Throughput Imaging and Genomics 3D Cell Culture-Based Screen siRNA Screening for Drug Target Identification Gene Editing for Drug Discovery Day 1 Stream 3: Discovery Chemistry, Medicinal and Computational Chemistry Modern Medicinal Chemistry Strategies Computational Chemistry Approaches and Drug Discovery From classical computational chemistry to data analysis and Data Integration Ligand Design – Case Studies in Molecular Structure Computation, Intermolecular Behaviour, Ligand-Receptor Interaction and Modelling Modern Approaches to Structure Based Design – Measuring and Predicting Drug Efficacy Fragment-Based Drug Discovery Hits to Leads and Integrating Leads from HTS Screens Day 2 Stream 3: Discovery Chemistry, Medicinal Chemistry and Drug Design: Novel Approaches Protein Kinases in Immunology and Oncology Inhibitors Discovery Strategies in Medicinal Chemistry FEP in Structure-based Discovery Peptide Discovery and Development DNA Coded Libraries Chemical Biology Targeted covalent inhibitors (TCIs) Immune Modulation PROTAC-induced BET protein degradation - therapy for castration-resistant prostate cancer Medicinal Chemistry for Autoimmune Diseases CNS – Interfacing Chemistry and Biology to Advance Neuroscience Drug Discovery Metabolic and Inflammation –Metabolic Profiling and Drug Target Discovery Novel Approaches to Drug Design and Development Complimentary registration to our pre-event webinars Email [email protected]
Transcript
Benefits to Attending
Hear from and meet with the people shaping the pharmaceutical landscape. 2017 attendees include: VPs of
Discover collaborative solutions to small molecule and large molecule drug discovery challenges. This summit
brings together experts on the best discovery techniques and technology, validating novel drug targets, improving lead
optimisation in different therapeutic areas including Immuno-Therapy, Autoimmune, Oncology, Inflammatory,
cardiovascular and metabolic diseases
Explore innovative Phenotypic screening, target based as well as RNAi screening methods
Gain from two discovery and computational chemistry streams to provide insights into modern medicinal chemistry
strategies, computational chemistry, FEP in structured based design, DNA coded libraries, automation, and novel
approaches to drug design
A stratified program ensuring tailored content –
Benefit from attending pre-event webinars, panel discussions and roundtable discussions on Novel Discovery Tools, Open Innovation, Artificial Intelligence, Phenotypic vs. target-based drug discovery, ADMET, Gene Editing and PROTAC
Unparalleled networking opportunities. The two-day
congress format combines dedicated networking breaks, pre-organised 1-2-1 meetings and our popular drinks reception. The exhibition hall and poster presentation spaces offer a relaxed and professional environment for discussion
Co-located with the Microbiome Discovery & Development Congress
Klaus Bæk Simonsen, Vice President, Lundbeck
Markus Haeberlein, Vice President, Discovery, Alkermes,
Nick Terrett ,Scientific Associate Vice President, , MSD
Constance Höfer, Chief Operating Officer, Priaxon
Peter Juhasz, Director, Mechanisms and Pathways, Biogen
Guido Hanauer, Scientific Director Translational Medicine, Takeda
For booking details & registration fees please refer to the last page or visit:
http://www.drugdiscovery-summit1.com/marketing
Day 1 Stream 1: Drug Discovery Innovation and Strategies, Enabling Technologies
Innovative Target Discovery and Discovery Models in: Metabolic and Cardiovascular Therapeutics, Cardiometabolic Drug Targets, Cancer Immunotherapy, Oncology and Neurological Diseases
Strategies in Target Validation and Lead Optimization
Managing Translational Informatics
Data Management in Discovery
Novel Drug Targets and Screening Tools
Managing Complex Discovery Portfolios
ADMET Drug Discovery
Day 2 Stream 1: Novel Drug Target Discovery for Immuno-Therapy, Autoimmune Diseases and Oncology
Discovery of T-Cell Cancer Immuno-Therapy
Novel Therapies for Cancer and Emerging Targets
Kinase Inhibitors: Cancer Immunotherapy Discovery, Autoimmune and Inflammatory Diseases, CNS and Neurodegenerative Disorders
Cancer metabolism /cancer metabolism targets - including anti-cachexic strategies
Day 1 Stream 2: Successful Phenotypic Drug Discovery: High Content Screening
Techniques and Tools in High Content Technologies
Phenotypic Screening Applications
3D Cell Based Screening Methods
Using Model Organisms for Screening Methods
Novel Approaches for Phenotypic Screening
Using Patient-Derived Tumour Models for Screening
Screening in Oncology and CNS Therapeutic Areas
High Content Screening & Data Management
Day 2 Stream 2: PART I - Open Innovation and Drug Discovery PART 2- RNAi Screening, Genomics Discovery and Gene Editing for Drug Discovery
Applications for Invivo RNAi Screening
Novel Applications in RNAi Screening
High-Throughput Imaging and Genomics
3D Cell Culture-Based Screen
siRNA Screening for Drug Target Identification
Gene Editing for Drug Discovery
Day 1 Stream 3: Discovery Chemistry, Medicinal and Computational Chemistry
Modern Medicinal Chemistry Strategies
Computational Chemistry Approaches and Drug Discovery
From classical computational chemistry to data analysis and Data Integration
Ligand Design – Case Studies in Molecular Structure Computation, Intermolecular Behaviour, Ligand-Receptor Interaction and Modelling
Modern Approaches to Structure Based Design – Measuring and Predicting Drug Efficacy
Fragment-Based Drug Discovery
Hits to Leads and Integrating Leads from HTS Screens
Day 2 Stream 3: Discovery Chemistry, Medicinal Chemistry and Drug Design: Novel Approaches
Protein Kinases in Immunology and Oncology
Inhibitors Discovery Strategies in Medicinal Chemistry
FEP in Structure-based Discovery
Peptide Discovery and Development
DNA Coded Libraries
Chemical Biology
Targeted covalent inhibitors (TCIs)
Immune Modulation
PROTAC-induced BET protein degradation - therapy for castration-resistant prostate cancer
Medicinal Chemistry for Autoimmune Diseases
CNS – Interfacing Chemistry and Biology to Advance Neuroscience Drug Discovery
Metabolic and Inflammation –Metabolic Profiling and Drug Target Discovery
Novel Approaches to Drug Design and Development
Complimentary registration to our pre-event webinars Email [email protected]
Herman van Vlijmen, Head, Computational Chemistry, Discovery Sciences EU, Janssen, Pharmaceutical Companies of Johnson & Johnson
Daniel Zwilling, Director of CNS Discovery, Circuit Therapeutics
Pierre Ducrot, Head of Chemoinformatic and Modeling, Servier
Melanie Leveridge, Head Screening, Profiling & Mechanistic Biology UK, RD Platform Technology & Science, GSK Medicines Research Centre
Brion W. Murray, Research Fellow, Senior Director, Pfizer Oncology Research Unit
Jonathan Mason, Senior Research Fellow CADD, Heptares Therapeutics & consultant Chief Scientist, Lundbeck Research
Stephen Hearty, Head of the Autoimmune Team, Immunocore
Jose Duca, Head, Computer-Aided Drug Discovery, Novartis
Nicolas Fischer, Head, Research, Novimmune
Niclas Nilsson, Head of R&D Open Innovation, LEO Pharma
Werngard Czechtizky, Head of Medicinal Chemistry, Sanofi
Ingo Muegge, Senior Research Fellow, Boehringer Ingelheim
Rod Hubbard, Professor & Senior Fellow, Vernalis
Andrew Payne, Senior Group Leader, UCB
Christian Fischer, Principal Scientist, Chemistry, MSD
Thierry Dorval, HCS – Group Leader, Biotechnology Chemical-Biology, Servier
Yolanda Chong, Principal Scientist, Johnson & Johnson
Francois Sautel, Open Innovation Leader, Institut de Recherche Pierre Fabre
Guido Zaman, Managing Director & Head of Biology, Netherlands Translational Research Center
Ton Rijnders, Scientific Director, Head of European Screening Center, Lygature
Fabio Gasparri, Head of Cell Assay Technologies, Nerviano Medical Sciences
Paul Andrews, Director of Operations, National Phenotypic Screening Centre (NPSC), School of Life Sciences, University of Dundee
Stefano Gustincich, Head Laboratory of Neurogenomics, Scuola Internazionale Superiore di Studi Avanzati
Complimentary registration to our pre-event webinars Email: [email protected] Drug Discovery Open Innovation and Outsourcing – 10th Feb 2017, 3.30 p.m. GMT
Patrick Kleyn, Director of Drug Target Innovation, EMD Serono
Garry Pairaudeau, Senior Director, Head of External Sciences, AstraZeneca
Phenotypic Screening in Drug Discovery- Novel Tools And Applications – 1st March 2017, 10.30 a.m. GMT
Paul Andrews, Director of Operations, National Phenotypic Screening Centre (NPSC), School of Life Sciences, University of Dundee
Disruptive Technologies and Artificial Intelligence in Drug Discovery– 21st March 2017, 4.00 pm GMT
If you’re on Twitter, make sure to follow us @drugdiscovery1 and join the Congress conversation on #DDSummit15 Meet Senior Decision Makers 250 VPs, Directors & Senior Managers from leading pharmaceutical organisations, biotech companies and academic institutions will attend the event. Delegate job titles include:
Small Molecule Drug discovery
Target selection
R&D Phenotypic Screening Drug design
Large Molecule Drug discovery
Lead optimisation
Open Innovation Rnai Screening Microbiome Discovery
Discover New Solutions Formal and informal meeting opportunities offer delegates the chance to discuss key solutions with leading service providers. Services to be discussed include:
Structure Based Drug Discovery
RNai Screening Phenotypic Screening
Target-Based Screening
Fragment based screening
Fragment Based Drug Discovery
PROTAC
Computational Chemistry
Peptides Discovery and Development
Inhibitor Discovery
Chemistry Disease Models
ADC Drug Design DNA Coded Libraries
Chemical Synthesis/Automation
Microbiome Discovery & Development
Modelling and Simulation
Lead Optimisation
Imaging Technology
ADME Data Analysis/Management/ Informatics
Target Validation Cellular Screening
High Throughput Cytometry
Library Optimisation
Lead Generation
Assay Development
PK/PD Translational Science Contract Drug Discovery Research
10.00 – 11.30 Morning Refreshments: Exhibition & Poster Presentation Session: One To One Meetings x4
11.30 – 12.00 Antibody-Enabled Small Molecule Drug Discovery
Alastair Lawson, VP Structural Biology, UCB
Target Discovery From Phenotypic Screens And Known Compounds With Unknown MoA Peter Juhasz, Director, Mechanisms and Pathways, Biogen
Acceleration of Drug Discovery and Development via Enabling Chemistry Technologies Steven Tevan Djuric, Distinguished Research Fellow, Senior Director, Discovery Chemistry and Technology, Abbvie
12.00 – 12.30 Solution Provider Presentation
Selvita
Solution Provider Presentation For sponsorship opportunities please contact
Novel Approaches For Phenotypic Screening Paul Andrews, Director of Operations, National Phenotypic Screening Centre (NPSC), School of Life Sciences, University of Dundee
Re-imagining Drug Discovery from a Computational Chemistry Perspective: New Methods on Binding Kinetics, Solvation and Dynamic Modelling
Use of first principles to advance the science of computational chemistry
Application to reverse kinetics, membrane partition and solvation
Prospective use on drug discovery projects
Paradigm change: use of dynamic modelling in early stages of drug discovery
Jose Duca, Head, Computer-Aided Drug Discovery, Novartis
15.30 – 16.30
Solution Provider Presentation For sponsorship opportunities please contact
16.30 – 17.30 Afternoon Refreshments: Exhibition & Poster Presentation Session, One To One Meetings x4
Drug Discovery Innovation and ADME Successful Phenotypic Drug Discovery Discovery Chemistry, Medicinal & Computational Chemistry
17.30 – 18.00 Applications Of Stable Labelled Isotopes In ADMET
Joel Krauser, Director, Novartis
Phenotypic-based Drug Discovery (TBC) Donna Finch, Associate Director, MedImmune
The Revelations of GPCR Structure-Based Drug Design: Implications For All Ligand Design Including Key Role Of Waters For Potency, Selectivity And Kinetics Jonathan Mason, Senior Research Fellow & Head CADD, Heptares Therapeutics
18.30 – 19.00 Broad Overview Of The Current And Future Perspectives On Screening Technologies Including perspectives on high content/phenotypic screening, label free screening and future directions
Melanie Leveridge, Head Screening, Profiling & Mechanistic Biology UK, RD Platform Technology & Science, GSK Medicines Research Centre
DNA Coded libraries - Innovative Technology For The Synthesis And Screening Of Chemical Libraries
Nils Jakob Vest Hansen, CEO, Vipergen ApS
19.00 – 19.30 ROUNDTABLE DISCUSSIONS: Topic 1: Screening Technologies – Which to choose? Moderator: Ton Rijnders, Scientific Director, Head of European Screening Center, Lygature Topic 2: Drug Discovery and Artificial Intelligence Proposed Moderator: Chris Gibson, CEO, Recursion Pharmaceuticals Topic 3: Successful Phenotypic Drug Discovery: High Content Screening Moderator: Jim Xu, Executive Director of Corporate Development/Strategic Planning, MSD Topic 4: Enabling Decision Making in Medicinal Chemistry Moderator: Ingo Mügge, Senior Research Fellow, Boehringer Ingelheim Pharmaceuticals Topic 5: Gene Editing in Drug Discovery Topic 6: PROTAC – Protein Degradation Moderator: Senior Representative, Merck Serono Topic 7: Open Innovation Moderator: Francois Sautel, Open Innovation Leader, Institut de Recherche Pierre Fabre Topic 8: Epigenetic Modulation in Cancer and Cardiovascular Diseases Topic 9: Translational Science of the Microbiome Moderator: Adam Baker, Head of Discovery – Microbiome and Human Health, Chr-Hansen A/S
17th Annual Drug Discovery Summit and 4th Annual Discovery Chemistry and Drug Design Congress Day 2 – 13th June 2017
Stream Chair
08.00 – 08.30 Drug Discovery Summit Keynote Presentation How To Improve Productivity In R+D Guido Hanauer, Scientific Director Translational Medicine, TAKEDA Pharmaceuticals
Discovery Chemistry & Drug Design Congress Keynote Presentation Modalities beyond the ‘rule of 5’ – will we ever make them drug-like? Nick Terrett ,Scientific Associate Vice President, European Chemistry Lead, MSD Research GmbH
Drug Discovery Summit Discovery Chemistry & Drug Design Congress
Drug Target Discovery For Immuno-Therapy, Autoimmune Diseases And Oncology
Open Innovation and Outsourcing Computation and Medicinal Chemistry and Drug Design: Novel Approaches
Stream 1 Chair: Stream Chair Stream Chair
08.30 – 09.00 Tumor-Localized Costimulatory T-cell Engagement Christine Rothe, Vice President, Head of Discovery & Alliance Management, Pieris
Open Collaboration To Enhance Target Innovation – Translating Novel Biology Into Leads For Drug Discovery
Share our experience of opening up our lead generation capabilities and scientific expertise to help academic drug discovery
The strategies and tactics we employ in Open Innovation partnerships at AstraZeneca
Key success factors and impactful case examples
Garry Pairaudeau, Senior Director, Head of External Sciences, AstraZeneca
Leveraging New Computational and Visualization Techniques to Impact Drug Discovery
10.00 – 11.20 Morning Refreshments, Exhibition & Poster Presentation Session, One To One Meetings x4
11.20 – 11.50 Strategy And Tactics For The Discovery Of Kinase Inhibitors For CNS Targets - A Lundbeck Perspective Klaus Bæk Simonsen, Vice President, Lundbeck
Creating Partnerships through Open Innovation initiatives
Open Innovation offers great chances in enhancing drug discovery:
How to drive innovation through initiation of intercompany collaborations with biotech companies, startups and academic groups. Tools and case studies.
Francois Sautel, Open Innovation Leader, Institut de Recherche Pierre Fabre
Prospective Applications of Free Energy Perturbation Calculations in Drug Discovery Herman van Vlijmen, Head, Computational Chemistry, Discovery Sciences EU, Janssen, Pharmaceutical Companies of Johnson & Johnson
17th Annual Drug Discovery Summit and 4th Annual Discovery Chemistry and Drug Design Congress
Day 2 – 13th June 2017
Drug Discovery Summit Discovery Chemistry & Drug Design Congress
Drug Target Discovery For Immuno-Therapy, Autoimmune Diseases And Oncology
Open Innovation and Outsourcing Medicinal Chemistry and Drug Design: Novel Approaches
11.50 – 12.20
Bispecific Antibody Approach Targeting An Immune
Checkpoint
Nicolas Fischer, Head, Research, Novimmune
The European Lead Factory: Results, Beneficiaries and Impact
Progress of public screening programs towards innovative drug discovery projects
Initial measures of performance of the new public compound collection
Future of the Public Private Partnership in early drug discovery
Ton Rijnders, Scientific Director, Head of European Screening Center, Lygature
Panel Discussion How to Take FEP Structure-Based Drug Design Forward In The Future
Panellists: Jonathan Mason, Senior Research Fellow & Head CADD, Heptares Therapeutics
Herman van Vlijmen, Head, Computational Chemistry, Discovery Sciences EU, Janssen, Pharmaceutical Companies of Johnson & Johnson
Jose Duca, Head, Computer-Aided Drug Discovery, Novartis
12.20 – 12.50
Drug Targets in Discovery and Development -
Autoimmune Diseases
Stephen Hearty, Head of the Autoimmune Team,
Immunocore
Use of Open Innovation As A Concrete Tool To Explore New Science And Partnerships
What can be achieved with Open Innovation in Drug Discovery
Expectations and critical change factors for implementation
A little less conversation, a little more action
Niclas Nilsson, Head of R&D Open Innovation, LEO Pharma
Large Synthetic Molecules – Opportunity & Challenge to Medicinal Chemistry Werngard Czechtizky, Head of Medicinal Chemistry, Sanofi
12.50 – 14.00 Lunch
Drug Target Discovery For Immuno-Therapy, Autoimmune Diseases And Oncology
RNAi Screening, Genomics Discovery and Gene Editing for Drug Discovery
Medicinal Chemistry and Drug Design: Novel Approaches
14.00 – 14.30
Translational Characterisation Of Seletalisib, A Novel Inhibitor Of PI3Kδ, In Immune-driven Disease Andrew Payne, Senior Group Leader, UCB
Applications For Invivo RNAi Screening In Vivo Validation Of Mutant IDH1 In Glioma: From uHTS Hits To Brain-penetrant Tool Compounds Mutations in Isocitrate Dehydrogenase (IDH) are prevalent in human glioma, in particular IDH1 R132H which is mutated in up to 80% of low grade gliomas. We have conducted a high throughput screen to identify compounds that inhibit IDH1 R132H selectively over the wild type enzyme. In this presentation we will discuss the outcome of the screen and our medicinal chemistry optimization strategy to arrive at potent, selective and orally bioavailable brain-penetrant inhibitors. We assessed the utility and potential therapeutic benefit of our optimized tool compounds in several IDH1 mutant in vivo models. These tool molecules achieved near complete inhibition of the mutant enzyme and provided significant survival benefit in a patient-derived orthotopic glioma model.
Christian Fischer, Principal Scientist, Chemistry, MSD
17th Annual Drug Discovery Summit and 4th Annual Discovery Chemistry and Drug Design Congress
Day 2 – 13th June 2017
Drug Discovery Summit Discovery Chemistry & Drug Design Congress
Drug Target Discovery For Immuno-Therapy, Autoimmune Diseases And Oncology
Open Innovation and Outsourcing Medicinal Chemistry and Drug Design: Novel Approaches
14.30 – 15.00 Can Physiological Relevance Enhance Target
Validation and Lead Optimization? A Tale Of Two
Kinases • In vitro physiologically relevant systems such as primary
human cells, 3D tissues, and IPSC-derived cells are
increasingly being used throughout the drug discovery process
• Recent scientific advancements and emerging technologies make these systems more accessible and are thus being applied earlier and earlier in lead discovery and optimization
• Given the potential species differences in biologies between rodent and humans, these systems are now being deployed also for target discovery and validation
• Two case studies will be discussed where primary human
immune cells have been used • In the first example, the role the T cell kinase ITK plays in
Th2 cytokine regulation was investigated in primary human
Th2 cells
• The second case study will discuss how a NIK small molecule lead optimization program was accelerated using a combination of primary human B cells and primary human hepatocytes to assess whole blood potency and in vitro clearance, respectively, with the goal to estimate human dose projections early in the discovery cascade
Hicham Alaoui, Director, Biochemical & Cellular
Pharmacology, Genentech
Cancer Genomics for Drug Discovery
Stefano Gustincich, Head Laboratory of Neurogenomics, Scuola Internazionale Superiore di Studi Avanzati (SISSA)
New Directions For Fragment Based Discovery Fragments to activate enzymes
Identifying potential targets in a molecular machine
Expanding diversity in fragment shape
Rod Hubbard, Professor & Senior Fellow, Vernalis
15.00 – 15.15 Afternoon Refreshments
15.15 – 15.45 Small Molecule Targeting Of The Wnt-pathway Guido Zaman, Managing Director & Head of Biology, Netherlands Translational Research Center
High-Throughput Imaging And Genomics Kinetic Parameters and Modification Matthias Frech, Director Molecular Interactions & Biophysics, Merck Serono
Invoice Address (if different from above)_______________________
*Please note there is a €65/£50 handling charge for payment via invoice *All card payments will be subject to a 3% bank charge or 4% AMEX charge
Registration Fees
Agreed Terms between the Organiser (Oxford Global Marketing Ltd) and the Delegate: Delegate Booking Fee The Delegate Booking Fee includes: lunches and refreshments throughout the Congress event, conference presentations, workshop and panel sessions, scheduled one-to-one meetings and networking/social events, conference and speaker notes. Delegates may attend, free of charge, all sessions arranged by the Organiser. An admin surcharge of €65/£50 will be applied to payments settled following the receipt of an invoice. This charge will not be applied to payments settled online. Vendor Delegates will not be eligible for one to one meetings unless they purchase a sponsorship meetings package. These can only be purchased directly from Oxford Global Marketing Ltd and not via the online booking facility. Poster Presentations Those who have booked a poster presentation at the event must provide the poster title, abstract (200 words or less), principal author, organisation, mailing address, email, telephone, fax and additional authors, within a month of registration. All poster spaces will be for A0 (841mm x 1189mm) portrait size. Cancellation and Curtailment Delegates and vendor delegates are subject to the following charges and refunds upon withdrawal or cancellation. More than 6 months prior 35% cancellation fee / 65% refund Between 6 and 3 months prior 75% cancellation fee/ 25% refund Less than 3 months prior to the event Full cancellation fee / No refund Data Protection The data controller is the Organiser. The Organiser may disclose such personal information to Registered Event Sellers (Solution Providers) and other Delegates but solely for the purposes of the Event. The Delegate consents to the use of his/her personal and company information on the terms set out herein. Miscellaneous This Agreement may not be transferred or assigned by either the Delegate or the Delegate’s Company. The Organiser will determine the scope and content of Congress conference events, seminars, workshops and activities throughout the Event. The Organiser reserves the right to cancel the Event without liability to Delegate’s Company or individual Delegate. If for any reason the Organiser has to cancel or postpone this Event, the Organiser reserves the right to transfer this Booking to another Congress within the same sector to be held within twelve months. Should another Congress in the same sector not be available within this period, the Booking Fee will be refunded.
I agree to the above Terms and Conditions
How to Pay (choose one of the following payment options)
I would like to attend: (Please tick as appropriate) Industry Delegates (Biopharma, Pharma or Biotech Companies)
Congress €985 £799 1 day pass €620 £499
Day 1 Day 2
Academic Delegates
Congress €620 £499 1 day pass €370 £299 Day 1 Day 2
Vendor Delegates (CROs, Consultants, Technology and Service Providers)
Congress Only €1665 £1350 1 day pass €985 £799
Day 1 Day 2
Poster Presentation €310 £250
PROMOTIONAL LITERATURE DISTRIBUTION
Distribution of your company’s promotional literature to all conference attendees €1210 £999
Documentation
I cannot attend but would like to purchase access to the following:
Access to the online conference presentations €620 £499 Conference presentations - paper copy €620 £499
If you have any further queries please call the marketing team on +44(0)1865 248455 or email [email protected]
![A simple fluorescent assay for the discovery of protein ...High throughput screening (HTS) is a key drug discovery tool [1,2]. With this advancement, the ambitions of scientific research](https://static.documents.pub/doc/80x56/5f2eecc939a15e71747a40de/a-simple-fluorescent-assay-for-the-discovery-of-protein-high-throughput-screening.jpg)
